Conflict of interest
Authors confirm that they have no conflict of interest to declare.
References :
1. Connors JM, Levy JH (2020) COVID-19 and its implications for
thrombosis and anticoagulation. Blood 135(23):2033-2040.
2. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS,
Reich NG, Lessler J (2020) The incubation period of coronavirus disease
2019 (COVID-19) from publicly reported confirmed cases: estimation and
application. Ann Intern Med
172(9):577-582.
3. Iba T, Levy JH, Levi M, Thachil J (2020) Coagulopathy in COVID‐19. J
Thromb Haemost 18(9): 2103-2109.
4. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao
H, Zhang H, Wang C (2020) Coagulopathy and antiphospholipid antibodies
in patients with Covid-19. NEJM 382(17): 38.
5. Barrett CD, Moore HB, Yaffe MB,
Moore EE (2020) ISTH interim guidance on recognition and management of
coagulopathy in COVID‐19: A Comment. J Thromb Haemost 18(8):2060-2063
6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL,
Hui DSC, Du B (2020) Clinical characteristics of coronavirus disease
2019 in China. NEJM 382(18):1708-1720.
7. Giannis D, Ziogas IA, Gianni P (2020) Coagulation disorders in
coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and
lessons from the past. J Clin Virol 127: 104362
8. Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters
are associated with poor prognosis in patients with novel coronavirus
pneumonia. J Thromb Haemost 18(4): 844-847
9. Lippi G, Plebani M, Henry BM
(2020) Thrombocytopenia is associated with severe coronavirus disease
2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta
506:
145-148
10. Dolhnikoff M, Duarte‐Neto AN, de Almeida Monteiro RA, Ferraz da
Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, Mauad T, Marcia
Negri E (2020) Pathological evidence of pulmonary thrombotic phenomena
in severe COVID‐19. J Thromb Haemost 18(6): 1517-1519
11. Yin S, Huang M, Li D, Tang N (2020) Difference of coagulation
features between severe pneumonia induced by SARS-CoV2 and
non-SARS-CoV2. J Thromb Thrombolysis doi: 10.1007/s11239-020-02105-8.
12. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, Chen X, Chen S, Yu K,
Huang Z, Hu B (2020) D-dimer as a biomarker for disease severity and
mortality in COVID-19 patients: a case control study. J Intensive Care
8(1): 1-11.
13. Subramaniam S, Scharrer I (2018) Procoagulant activity during viral
infections. Front Biosci (Landmark Ed) 23: 1060-1081
14. Rondina MT, GUO L (2019) The era
of thromboinflammation: platelets are dynamic sensors and effector cells
during infectious diseases. Front Immunol 10:2204
15. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM,
Marchese P, Frelinger AL, Goldberg RJ, Michelson AD (2001) Circulating
monocyte-platelet aggregates are an early marker of acute myocardial
infarction. J Am Coll Cardiol 38 (4): 1002-1006
Table 1: Demographic characteristics, underlying disease and length of
hospital stay of patients by groups